NO942323L - Soy protein or hydrolysates in pharmaceutical compositions for the protection of bioactive peptides against enzymatic inactivation - Google Patents

Soy protein or hydrolysates in pharmaceutical compositions for the protection of bioactive peptides against enzymatic inactivation

Info

Publication number
NO942323L
NO942323L NO942323A NO942323A NO942323L NO 942323 L NO942323 L NO 942323L NO 942323 A NO942323 A NO 942323A NO 942323 A NO942323 A NO 942323A NO 942323 L NO942323 L NO 942323L
Authority
NO
Norway
Prior art keywords
hydrolysates
protection
pharmaceutical compositions
enzymatic inactivation
soy protein
Prior art date
Application number
NO942323A
Other languages
Norwegian (no)
Other versions
NO942323D0 (en
Inventor
Gordon L Amidon
Glen D Leesman
Patrick J Sinko
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO942323D0 publication Critical patent/NO942323D0/en
Publication of NO942323L publication Critical patent/NO942323L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Proteiner eller peptider som kan fremstilles fra naturlig forekommende proteiner, oker biotilgjengeligheten til proteolytisk labile, terapeutiske midler som, i fravær av protein- eller peptid-stoffet, ville utsettes for enzymatisk inaktivering ved administrering.Proteins or peptides that can be prepared from naturally occurring proteins increase the bioavailability of proteolytically labile therapeutic agents which, in the absence of the protein or peptide substance, would be subjected to enzymatic inactivation upon administration.

NO942323A 1991-12-18 1994-06-17 Soy protein or hydrolysates in pharmaceutical compositions for the protection of bioactive peptides against enzymatic inactivation NO942323L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81059391A 1991-12-18 1991-12-18
PCT/US1992/009336 WO1993011799A1 (en) 1991-12-18 1992-11-09 Soybean protein or hydrolyzates in pharmaceutical compositions to protect bioactive peptides from enzymatic inactivation

Publications (2)

Publication Number Publication Date
NO942323D0 NO942323D0 (en) 1994-06-17
NO942323L true NO942323L (en) 1994-06-17

Family

ID=25204183

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942323A NO942323L (en) 1991-12-18 1994-06-17 Soy protein or hydrolysates in pharmaceutical compositions for the protection of bioactive peptides against enzymatic inactivation

Country Status (12)

Country Link
EP (1) EP0617626A1 (en)
JP (1) JPH06510796A (en)
AU (1) AU3058392A (en)
CA (1) CA2125400A1 (en)
FI (1) FI942938A (en)
HU (1) HUT69785A (en)
IL (1) IL104048A0 (en)
MX (1) MX9207407A (en)
NO (1) NO942323L (en)
PT (1) PT101135A (en)
WO (1) WO1993011799A1 (en)
ZA (1) ZA929761B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950703333A (en) * 1992-10-02 1995-09-20 알렌 제이. 스피겔 Pharmaceutical Compositions Containing Nonionic Surfactants
AU7273494A (en) * 1993-09-01 1995-03-22 Pfizer Inc. Pharmaceutical compositions containing anionic surfactants
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DE19530865A1 (en) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Active ingredient and agent for parenteral nutrition
MXPA02007202A (en) * 2000-01-27 2003-09-22 Peros Syst Mes Technologies In Composition for intestinal delivery.
GB0015921D0 (en) * 2000-06-30 2000-08-23 Nat Biolog Standards Board Improvements in or relating to stabilisation of substances
CL2008001640A1 (en) * 2007-06-08 2008-11-07 Bergen Teknologioverforing As Use of hydroxyproline to prepare an alloy composition intended to promote the growth of an animal, such as fish, birds and mammals.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4774089A (en) * 1985-06-14 1988-09-27 Albion International, Inc. Stimulation of gonadotropic hormones with mineral mixtures containing amino acid chelates
MY103189A (en) * 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
DE3887494T2 (en) * 1987-11-13 1994-05-19 Smithkline Beecham Farma Medicines containing a calcitonin and a glycyrrhizinate as absorption promoter.
EP0341661A3 (en) * 1988-05-11 1991-05-02 The Du Pont Merck Pharmaceutical Company Peptide-drug compositions containing alpha-aminoboronic acid derivatives
DD273980B5 (en) * 1988-07-12 1994-04-14 Berlin Chemie Ag Process for the preparation of insulin preparations for rectal use
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
DK546289D0 (en) * 1989-11-02 1989-11-02 Danochemo As carotenoid

Also Published As

Publication number Publication date
PT101135A (en) 1994-03-31
AU3058392A (en) 1993-07-19
HUT69785A (en) 1995-09-28
EP0617626A1 (en) 1994-10-05
HU9401824D0 (en) 1994-09-28
NO942323D0 (en) 1994-06-17
MX9207407A (en) 1993-06-01
CA2125400A1 (en) 1993-06-24
WO1993011799A1 (en) 1993-06-24
FI942938A0 (en) 1994-06-17
FI942938A (en) 1994-06-17
IL104048A0 (en) 1993-05-13
ZA929761B (en) 1994-06-17
JPH06510796A (en) 1994-12-01

Similar Documents

Publication Publication Date Title
Rami et al. Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity
Mirzapour et al. Identification of potent ACE inhibitory peptides from wild almond proteins
ES2178000T3 (en) COMPOSITIONS AND METHODS TO TREAT INFECTIONS USING INDOLICIDINE ANALOGS.
BR9907995A (en) Immunological methods to modulate myostatin in vertebrate subjects
BR0108402A (en) Modified monocyclic carboxamidine-based nucleoside analogs
BR0112666A (en) Peptides as inhibitors of hepatitis C virus ns3-serine protease
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
TR199701071T2 (en) Compounds and compositions for delivery of the active substance.
CY1106769T1 (en) LYOPHILISABLE PHARMACEUTICAL COMPOSITION OF PHARMACEUTICAL DRUG FOR SIMULATION OF A DRUG, ESPECIALLY PROTEIN OR POLYPEPTIDE BASED
ES2174855T3 (en) DIAGNOSTIC METHODS AND PHARMACEUTICAL COMPOSITIONS BASED ON NOTCH PROTEINS AND NUCLEIC ACIDS.
DE69532996D1 (en) PEPTIDE ANALOGS OF THE HUMAN BASIC MYELINE PROTEIN
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
ATE144535T1 (en) PLATE BLOCKING PEPTIDES
DE69937798D1 (en) PEPTIDES BASED ON THE SEQUENCE OF HUMAN LACTOFERRINE AND ITS APPLICATION
SE0002202D0 (en) New peptides
ATE234111T1 (en) THERAPEUTIC USES OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BLEEDING CAUSED BY TRAUMA
DE69900756T2 (en) USE OF HMG PROTEINS FOR THE PRODUCTION OF MEDICINAL PRODUCTS WITH A CYTOTOXIC EFFECT
NO942323L (en) Soy protein or hydrolysates in pharmaceutical compositions for the protection of bioactive peptides against enzymatic inactivation
CO5570658A2 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETES
HK1066551A1 (en) Tolerogenic peptides from myelin basic protein
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
ATE359296T1 (en) PHARMACEUTICAL PEPTIDE FORMULATIONS FOR THE TREATMENT OF DUST MITE ALLERGY
FR2569111B1 (en) NEW DRUGS CONTAINING TRIPEPTIDES
EP1174439A3 (en) Compositions and methods for treating infections using analogues of indolicidin
ATE184287T1 (en) DERIVATIVES OF PEPTIDES THERAPEUTICALLY EFFECTIVE IN THE BLOOD CLOTTING CAScade, METHOD FOR THE PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME